Farallon Capital Management’s Assembly Biosciences ASMB Stock Holding History

Farallon Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.1M	Hold	1,227,590	–	–	0.19%	52
2025 Q4	$41.8M	Hold	1,227,590	–	–	0.19%	57
2025 Q3	$31.4M	Buy	+1,227,590	New	+$26.9M	0.13%	65
2019 Q3	–	Sell	-8,333	Closed	-$1.35M	–	102
2019 Q2	$1.35M	Hold	8,333	–	–	0.01%	101
2019 Q1	$1.97M	Sell	8,333 -20,834	-71%	-$5.27M	0.01%	92
2018 Q4	$7.92M	Buy	29,167 +4,167	+17%	+$1.21M	0.06%	86
2018 Q3	$11.1M	Buy	+25,000	New	+$11.7M	0.07%	83
2018 Q1	–	Sell	-20,833	Closed	-$11.3M	–	90
2017 Q4	$11.3M	Buy	+20,833	New	+$9.43M	0.09%	65

Other funds holding ASMB

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Farallon Capital Management's ASMB Position: Q1 2026 in Review

Farallon Capital Management held its Assembly Biosciences (ASMB) position steady in Q1 2026 at 1,227,590 shares worth $34.1M. The position accounts for 0.19% of the portfolio, ranked #52.

Farallon Capital Management first reported a position in ASMB in Q4 2017 and has held it in 8 quarters since. The position peaked at $41.8M in Q4 2025. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

Farallon Capital Management held 1,227,590 shares of Assembly Biosciences worth $34.1M as of Q1 2026.
Farallon Capital Management left its Assembly Biosciences share count unchanged in Q1 2026.
Assembly Biosciences made up 0.19% of Farallon Capital Management's portfolio in Q1 2026, its #52 holding.
Farallon Capital Management first reported a position in Assembly Biosciences in Q4 2017 and has held it in 8 quarters since.
Farallon Capital Management's Assembly Biosciences position peaked at $41.8M in Q4 2025.
75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.